Brainstorm Cell TherapeuticsBCLI
13F holders, Q3 2024 (September 30)34holders −14
3new positions
17sold out
$0.23avg. 13F price*
At the end of Q3 2024, 34 institutions reported holding Brainstorm Cell Therapeutics (BCLI) in their 13F filings, down 14 from Q2 2024. 3 opened new positions and 17 sold out. The largest holders were Armistice Capital, LLC ($1.6M), Vanguard Group Inc. ($347K) and Geode Capital Management, LLC ($152K).
- Company
- Brainstorm Cell Therapeutics
- CUSIP
- 10501E201
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $15K |
| Exits | 17 | $132K |
All 13F filers, Q2 2024 → Q3 2024: 300,217 shares bought and 1,738,570 shares sold, net −1,438,353 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 34 holders
| Armistice Capital, LLC | 0.04% | Reduce -12.9% | 6,897,653 | $1.6M |
| Vanguard Group Inc. | 0.00% | No change | 1,510,640 | $347K |
| Geode Capital Management, LLC | 0.00% | Add +41.0% | 682,816 | $152K |
| BlackRock, Inc. | 0.00% | — | 377,611 | $87K |
| Liberty Wealth Management LLC | 0.01% | No change | 340,150 | $78K |
| Weaver Consulting Group | 0.02% | No change | 234,356 | $54K |
| State Street Corp. | 0.00% | No change | 117,260 | $27K |
| Northern Trust Corp. | 0.00% | No change | 112,358 | $26K |
| Raymond James & Associates | 0.00% | Reduce -14.5% | 95,153 | $22K |
| Jmac Enterprises LLC | 0.00% | No change | 65,430 | $15K |
| XTX Topco Ltd | 0.00% | New | 53,088 | $12K |
| Wells Fargo & Company | 0.00% | Add +83.2% | 52,777 | $12K |
| Morgan Stanley | 0.00% | Add +33.8% | 49,463 | $11K |
| Group One Trading LLC | 0.00% | No change | 46,754 | $11K |
| Tru Independence Asset Management 2, LLC | 0.01% | — | 44,000 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -73.0% | 23,356 | $5K |
| Janney Montgomery Scott LLC | 0.00% | No change | 20,500 | $5K |
| Two Sigma Securities, LLC | 0.00% | Reduce -80.6% | 19,796 | $5K |
| Creative Planning | 0.00% | Reduce -33.8% | 13,846 | $3K |
| Saxony Capital Management, LLC | 0.00% | No change | 12,950 | $3K |
| Bank of New York Mellon Corp | 0.00% | No change | 11,994 | $3K |
| Jump Financial, LLC | 0.00% | New | 10,995 | $3K |
| Osaic Holdings, Inc. | 0.00% | No change | 10,519 | $2K |
| Activest Wealth Management | 0.00% | Reduce -29.2% | 5,010 | $1K |
| Bangor Savings Bank | 0.00% | No change | 4,000 | $921 |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 2,700 | $622 |
| UBS Group AG | 0.00% | Reduce -64.8% | 2,501 | $575 |
| Bank of America Corp. | 0.00% | Add +7.7% | 1,607 | $370 |
| Clearstead Advisors, LLC | 0.00% | No change | 1,500 | $346 |
| Fourpath Capital Management, LLC | 0.00% | New | 1,034 | $238 |
| Westside Investment Management, Inc. | 0.00% | No change | 200 | $46 |
| JPMorgan Chase & Co. | 0.00% | Reduce -31.4% | 175 | $40 |
| Northwestern Mutual Wealth Management Co. | 0.00% | No change | 161 | $37 |
| Simplex Trading, LLC | 0.00% | Reduce -79.1% | 1,150 | $0 |
"% of holder's portfolio" is BCLI's weight in each manager's 13F, not the share of Brainstorm Cell Therapeutics the manager owns.